[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2007047575A3 - Pharmacological treatments for sleep-related breathing disorders - Google Patents

Pharmacological treatments for sleep-related breathing disorders Download PDF

Info

Publication number
WO2007047575A3
WO2007047575A3 PCT/US2006/040362 US2006040362W WO2007047575A3 WO 2007047575 A3 WO2007047575 A3 WO 2007047575A3 US 2006040362 W US2006040362 W US 2006040362W WO 2007047575 A3 WO2007047575 A3 WO 2007047575A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
vanilloid
sleep
breathing disorders
related breathing
Prior art date
Application number
PCT/US2006/040362
Other languages
French (fr)
Other versions
WO2007047575A2 (en
Inventor
David W Carley
Miodrag Radulovacki
Original Assignee
Univ Illinois
David W Carley
Miodrag Radulovacki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, David W Carley, Miodrag Radulovacki filed Critical Univ Illinois
Publication of WO2007047575A2 publication Critical patent/WO2007047575A2/en
Publication of WO2007047575A3 publication Critical patent/WO2007047575A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders, in particular sleep apnea. The method comprises administration to a patient in need thereof an effective dose of one or a combination of vanilloid receptor ligands. The vanilloid receptor ligand or combination of vanilloid receptor ligands can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabimimetic agents, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, one or more inhibitors of vanilloid synthesis or vanilloid release, or any combination of the foregoing.
PCT/US2006/040362 2005-10-14 2006-10-13 Pharmacological treatments for sleep-related breathing disorders WO2007047575A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72670805P 2005-10-14 2005-10-14
US60/726,708 2005-10-14

Publications (2)

Publication Number Publication Date
WO2007047575A2 WO2007047575A2 (en) 2007-04-26
WO2007047575A3 true WO2007047575A3 (en) 2007-07-12

Family

ID=37762448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040362 WO2007047575A2 (en) 2005-10-14 2006-10-13 Pharmacological treatments for sleep-related breathing disorders

Country Status (1)

Country Link
WO (1) WO2007047575A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520883A (en) * 2009-03-16 2012-09-10 アイピントゥル，エルエルシー Treatment of Alzheimer's disease and osteoporosis and reduction of aging
KR102587297B1 (en) 2017-08-31 2023-10-12 (주)아모레퍼시픽 A composition for preventing or treating sleep disturbance
KR102587300B1 (en) 2017-08-31 2023-10-12 (주)아모레퍼시픽 A composition for preventing or treating for atopic dermatitis
WO2024124172A1 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for stimulating and/or enhancing exercise motivation and/or physical performance

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016318A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002080903A1 (en) * 2001-04-06 2002-10-17 The Board Of Trustees Of The University Of Illinois Functional role for cannabinoids in autonomic stability during sleep
WO2003027064A1 (en) * 2001-09-27 2003-04-03 Digital Biotech Co. Ltd,. Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical co mpositions containing the same
WO2003080036A2 (en) * 2002-03-25 2003-10-02 Lmd Use of a vanilloid as an anti-snoring element
FR2860514A1 (en) * 2003-10-03 2005-04-08 Sanofi Synthelabo ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2006133197A1 (en) * 2005-06-06 2006-12-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating sleep disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016318A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002080903A1 (en) * 2001-04-06 2002-10-17 The Board Of Trustees Of The University Of Illinois Functional role for cannabinoids in autonomic stability during sleep
WO2003027064A1 (en) * 2001-09-27 2003-04-03 Digital Biotech Co. Ltd,. Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical co mpositions containing the same
WO2003080036A2 (en) * 2002-03-25 2003-10-02 Lmd Use of a vanilloid as an anti-snoring element
FR2860514A1 (en) * 2003-10-03 2005-04-08 Sanofi Synthelabo ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2006133197A1 (en) * 2005-06-06 2006-12-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating sleep disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
APPENDINO G ET AL: "TRPV1 (VANILLOID RECEPTOR, CAPSAICIN RECEPTOR) AGONISTS AND ANTAGONISTS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 13, no. 12, 2003, pages 1825 - 1837, XP002320750, ISSN: 1354-3776 *
CARLEY D W ET AL: "C-fiber activation exacerbates sleep-disordered breathing in rats.", SLEEP & BREATHING = SCHLAF & ATMUNG SEP 2004, vol. 8, no. 3, September 2004 (2004-09-01), pages 147 - 154, XP002423253, ISSN: 1520-9512 *
GERAGHTY DOMINIC P ET AL: "RESPIRATORY ACTIONS OF VANILLOID RECEPTOR AGONISTS IN THE NUCLEUS OF THE SOLITARY TRACT: COMPARISON OF RESINIFERATOXIN WITH NON-PUNGENT AGENTS AND ANANDAMIDE", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 137, no. 6, 2002, pages 919 - 927, XP008075862, ISSN: 0007-1188 *
SABOGAL CARLOS ET AL: "PROTECTIVE EFFECT OF PALIVIZUMAB AGAINST CAPSAICIN-INDUCED APNEA/HYPOPNEA IN RESPIRATORY SYNCYTIAL VIRUS (RSV)-INFECTED F-344 RATS", PEDIATRIC RESEARCH, WILLIAMS AND WILKINS, BALTIMORE, MD,, US, vol. 51, no. 4 PT 2, April 2002 (2002-04-01), pages 395A, XP008075769, ISSN: 0031-3998 *
SZALLASI A: "VANILLOID RECEPTOR LIGANDS HOPES AND REALITIES FOR THE FUTURE", DRUGS AND AGING, ADIS INTERNATIONAL LTD, NZ, vol. 18, no. 8, 2001, pages 561 - 573, XP001105341, ISSN: 1170-229X *

Also Published As

Publication number Publication date
WO2007047575A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
JP2010535252A5 (en)
CR10627A (en) THERAPEUTIC METHODS FOR THE TREATMENT OF VASCULAR OCULAR DISORDERS WITH DII4 ANTAGONISTS
JP2007521835A5 (en)
BRPI1011220A2 (en) pharmaceutical composition, methods of treating a disease or disorder, for the respiratory administration of two or more active agents, for the respiratory administration of a combination of active agents, and for preparing a suitable composition.
CR10342A (en) INHIBITORS OF THE IAS CHANNELS TASK-1 and TASK-3
HK1104471A1 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
WO2010015260A3 (en) Administration by infusion for the treatment of ischemic effects
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
EA201170018A1 (en) Razagilin to change the flow of Parkinson's disease
CY1112320T1 (en) TAPENDADOL TITLE
WO2009127974A3 (en) Pharmaceutical formulation for treating cardiovascular disease
RS52867B (en) Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
NO20052420L (en) Pharmacological treatment of sleep apnea ±.
Ayatollahi et al. Effect of intravenous vitamin C on postoperative pain in uvulopalatopharyngoplasty with tonsillectomy
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2009011900A (en) Diabetic wound healing.
BRPI0804623A2 (en) use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive impairment
WO2007047575A3 (en) Pharmacological treatments for sleep-related breathing disorders
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
DK1715859T3 (en) Method of treating and diagnosing respiratory disorders in sleep by zonisamide and means for carrying out the method
Tuncer et al. The pre‐emptive analgesic effect of intra‐articular bupivacaine in arthroscopic knee surgery
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06816989

Country of ref document: EP

Kind code of ref document: A2